IGNYTA, INC. (NASDAQ:RXDX) Files An 8-K Results of Operations and Financial ConditionItem 2.02.
On August8, 2017, Ignyta, Inc. issued a press release announcing its results of operations for the three-month period ended June30, 2017. The full text of such press release is furnished as Exhibit 99.1 to this report.
In accordance with General Instruction B.2. of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to this Current Report on Form 8-K.
| Item 2.02. | Financial Statements and Exhibits |
(d)Exhibits.
The following press release is furnished as an exhibit to this Current Report on Form 8-K to Item 2.02 and shall not be deemed to be “filed”:
|
ExhibitNo. |
Description |
| 99.1 | Press Release, dated August8, 2017. |
Ignyta, Inc. ExhibitEX-99.1 2 d437757dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Ignyta Announces Second Quarter 2017 Company Highlights and Financial Results August 8,…To view the full exhibit click here
About IGNYTA, INC. (NASDAQ:RXDX)
Ignyta, Inc. is an oncology biotechnology company. The Company focuses on an integrated therapeutic (Rx) and companion diagnostic (Dx) strategy for treating cancer patients. Its Rx is focused on discovering, in licensing or acquiring, then developing and commercializing molecularly targeted therapies that, sequentially or in combination, are foundational for eradicating residual disease. Its Dx focuses on pairing the product candidates with biomarker-based companion diagnostics that are designed to identify, at the molecular level, the patients likely to benefit from the therapies. Its entrectinib is an orally bioavailable, small molecule tyrosine kinase inhibitor directed to the tropomyosin receptor kinase (Trk) family tyrosine kinase receptors (TrkA, TrkB and TrkC), ROS1 and anaplastic lymphoma kinase (ALK) proteins for the treatment of solid tumors. Its entrectinib is in Phase II/III of clinical development. Its taladegib is a small molecule and hedgehog or smoothened antagonist.
